Sodium Chloride side effects: what 78,465 FDA adverse event reports show
Drug class
Not stated in label
Who reports
78,465 reports · 80% serious · 6,827 with death outcome · 59% female
Used for
14.6% Sodium Chloride Injection, USP Additive Solution is indicated for parenteral restoration of sodium ion in patients with restricted oral intake. Sodium replacement is specifically indicated in patients with hyponatremia or low salt syndrome. 14.6% Sodium Chloride Additive Solution may also be added to compatible carbohydrate solutions such as dextrose in water to provide electrolytes.
What it is
DESCRIPTION 14.6% Sodium Chloride Injection, USP Additive Solution is a sterile, nonpyrogenic, concentrated solution for intravenous administration ONLY AFTER DILUTION to replenish electrolytes.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,194 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Vaginal flatulence | 119 | 170.7 135.5–215.0ROR 170.9 · calibrated p 2e-9 ✓ | 102.2 EB05 87.7 · IC025 +5.9 3/3 methods agree | Not in label — unassessed | serious n=119 · ♀ 100% (drug 59%) | no trial arm names this drug |
| Device wireless communication issue | 80 | 125.7 96.3–164.1ROR 125.9 · calibrated p 3e-8 ✓ | 83.7 EB05 69.4 · IC025 +5.4 3/3 methods agree | Reporting / coding artifact | 100% consumer | no trial arm names this drug |
| Deafness permanent | 56 | 105.7 77.6–144.2ROR 105.8 · calibrated p 1e-7 ✓ | 73.8 EB05 59.0 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious n=56 | no trial arm names this drug |
| Device maintenance issue | 120 | 72.1 58.9–88.2ROR 72.2 · calibrated p 1e-6 ✓ | 56.3 EB05 48.3 · IC025 +5.2 3/3 methods agree | Reporting / coding artifact | serious n=47 · 100% consumer | no trial arm names this drug |
| Infusion site discharge | 300 | 56.7 50.1–64.3ROR 56.9 · calibrated p 6e-6 ✓ | 46.7 EB05 42.4 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=182 · 87% consumer | no trial arm names this drug |
| Wound infection pseudomonas | 53 | 54.6 40.6–73.3ROR 54.6 · calibrated p 1e-5 ✓ | 44.7 EB05 35.5 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=53 · ♀ 100% (drug 59%) · 100% clinician | no trial arm names this drug |
| Granulocyte count decreased | 298 | 53.5 47.3–60.6ROR 53.7 · calibrated p 9e-6 ✓ | 44.5 EB05 40.4 · IC025 +5.2 3/3 methods agree | Lab value / disease marker | serious n=298 | no trial arm names this drug |
| Myelosuppression | 5,180 | 47.9 46.5–49.3ROR 51.2 · calibrated p 1e-5 ✓ | 40.6 EB05 39.7 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 42.1 · serious PRR 29.3 · 92% clinician | no trial arm names this drug |
| Infective pulmonary exacerbation of cystic fibrosis | 796 | 45.3 42.0–48.8ROR 45.7 · calibrated p 2e-5 ✓ | 38.7 EB05 36.5 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious n=727 | no trial arm names this drug |
| Ejection fraction | 78 | 41.0 32.3–52.1ROR 41.1 · calibrated p 6e-5 ✓ | 35.3 EB05 29.2 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=78 · ♀ 100% (drug 59%) | no trial arm names this drug |
| Cystic fibrosis respiratory infection suppression | 119 | 40.6 33.5–49.3ROR 40.7 · calibrated p 5e-5 ✓ | 35.1 EB05 30.1 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=119 · 100% consumer | no trial arm names this drug |
| Osmotic demyelination syndrome | 97 | 40.2 32.5–49.8ROR 40.3 · calibrated p 6e-5 ✓ | 34.8 EB05 29.4 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=97 · 100% clinician | no trial arm names this drug |
| Sensitisation | 99 | 39.6 32.0–48.9ROR 39.6 · calibrated p 7e-5 ✓ | 34.3 EB05 29.0 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=99 · ♀ 100% (drug 59%) | no trial arm names this drug |
| Device infusion issue | 294 | 36.3 32.2–41.0ROR 36.5 · calibrated p 9e-5 ✓ | 32.0 EB05 29.0 · IC025 +4.7 3/3 methods agree | Reporting / coding artifact | serious n=169 · 80% consumer | no trial arm names this drug |
| Infusion site haemorrhage | 376 | 35.0 31.4–38.9ROR 35.1 · calibrated p 1e-4 ✓ | 30.9 EB05 28.4 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=192 · 81% consumer | no trial arm names this drug |
| Infusion site irritation | 140 | 33.8 28.4–40.3ROR 33.9 · calibrated p 2e-4 ✓ | 30.0 EB05 26.0 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=52 · ♀ 82% (drug 59%) · 100% consumer | no trial arm names this drug |
| Endocrine ophthalmopathy | 90 | 32.5 26.1–40.5ROR 32.6 · calibrated p 2e-4 ✓ | 28.9 EB05 24.2 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=90 | no trial arm names this drug |
| Infusion site discomfort | 109 | 31.8 26.1–38.8ROR 31.8 · calibrated p 2e-4 ✓ | 28.3 EB05 24.1 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=61 · 100% consumer | no trial arm names this drug |
| Interleukin level increased | 53 | 29.3 22.1–39.0ROR 29.4 · calibrated p 4e-4 ✓ | 26.3 EB05 20.9 · IC025 +4.0 3/3 methods agree | Lab value / disease marker | serious n=53 · ♀ 0% (drug 59%) · 100% clinician | no trial arm names this drug |
| Cystic fibrosis | 538 | 28.5 26.1–31.2ROR 28.7 · calibrated p 3e-4 ✓ | 25.8 EB05 24.0 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=521 | no trial arm names this drug |
| Acidosis hyperchloraemic | 56 | 28.0 21.3–36.9ROR 28.0 · calibrated p 5e-4 ✓ | 25.2 EB05 20.1 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=55 · ♀ 0% (drug 59%) · 100% clinician | no trial arm names this drug |
| Infusion site induration | 134 | 27.7 23.2–33.1ROR 27.8 · calibrated p 4e-4 ✓ | 25.1 EB05 21.7 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | ♀ 81% (drug 59%) · 100% consumer | no trial arm names this drug |
| Infusion site mass | 99 | 27.2 22.1–33.5ROR 27.2 · calibrated p 5e-4 ✓ | 24.6 EB05 20.8 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=56 · ♀ 100% (drug 59%) · 100% consumer | no trial arm names this drug |
| Infusion site discolouration | 79 | 26.9 21.3–33.9ROR 26.9 · calibrated p 5e-4 ✓ | 24.4 EB05 20.2 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | ♀ 100% (drug 59%) · 100% consumer | no trial arm names this drug |
| Infusion site swelling | 557 | 26.5 24.3–28.9ROR 26.7 · calibrated p 5e-4 ✓ | 24.1 EB05 22.5 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=271 · 76% consumer | no trial arm names this drug |
| Infusion site inflammation | 61 | 26.5 20.3–34.4ROR 26.5 · calibrated p 6e-4 ✓ | 24.0 EB05 19.3 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | 100% consumer | no trial arm names this drug |
| Infusion site pain | 1,153 | 26.4 24.9–28.1ROR 26.8 · calibrated p 5e-4 ✓ | 24.1 EB05 23.0 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | age-adj. PRR 16.5 · serious n=498 · 79% consumer | no trial arm names this drug |
| Infusion site warmth | 106 | 25.7 21.1–31.4ROR 25.8 · calibrated p 6e-4 ✓ | 23.4 EB05 19.9 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=46 · 100% consumer | no trial arm names this drug |
| Infusion site erythema | 712 | 25.0 23.2–27.0ROR 25.2 · calibrated p 7e-4 ✓ | 22.9 EB05 21.5 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=331 · 80% consumer | no trial arm names this drug |
| Infusion site pruritus | 262 | 24.4 21.5–27.7ROR 24.5 · calibrated p 8e-4 ✓ | 22.4 EB05 20.2 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=160 · ♀ 80% (drug 59%) · 79% consumer | no trial arm names this drug |
| Infusion site infection | 185 | 23.7 20.4–27.5ROR 23.7 · calibrated p 9e-4 ✓ | 21.7 EB05 19.2 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=87 · ♀ 81% (drug 59%) · 82% consumer | no trial arm names this drug |
| Infusion site bruising | 168 | 22.8 19.5–26.7ROR 22.9 · calibrated p 0.001 ✓ | 21.0 EB05 18.5 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=116 · ♀ 80% (drug 59%) | no trial arm names this drug |
| Hereditary angioedema | 817 | 22.5 20.9–24.1ROR 22.7 · calibrated p 0.001 ✓ | 20.8 EB05 19.6 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious PRR 15.9 · ♀ 85% (drug 59%) | no trial arm names this drug |
| Infusion site rash | 105 | 22.2 18.2–27.1ROR 22.3 · calibrated p 0.001 ✓ | 20.5 EB05 17.4 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=68 | no trial arm names this drug |
| Female genital tract fistula | 129 | 21.6 18.0–25.8ROR 21.6 · calibrated p 0.001 ✓ | 20.0 EB05 17.2 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=128 · ♀ 100% (drug 59%) | no trial arm names this drug |
| Incorrect product formulation administered | 63 | 21.5 16.7–27.8ROR 21.5 · calibrated p 0.002 ✓ | 19.9 EB05 16.1 · IC025 +3.7 3/3 methods agree | Reporting / coding artifact | ♀ 100% (drug 59%) · 100% consumer | no trial arm names this drug |
| Blood fibrinogen decreased | 75 | 19.1 15.1–24.1ROR 19.1 · calibrated p 0.003 ✓ | 17.8 EB05 14.6 · IC025 +3.6 3/3 methods agree | Lab value / disease marker | serious n=75 | no trial arm names this drug |
| Chronic sinusitis | 249 | 18.9 16.7–21.5ROR 19.0 · calibrated p 0.003 ✓ | 17.7 EB05 15.9 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=242 · ♀ 100% (drug 59%) | no trial arm names this drug |
| Catheter site swelling | 58 | 17.9 13.7–23.4ROR 17.9 · calibrated p 0.004 ✓ | 16.7 EB05 13.4 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | 100% consumer | no trial arm names this drug |
| Polycystic ovaries | 98 | 17.7 14.4–21.7ROR 17.7 · calibrated p 0.004 ✓ | 16.6 EB05 14.0 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=98 · ♀ 100% (drug 59%) | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Hyponatraemia | 1,513 | 5.14.8–5.4 | signal |
| Neutropenia / agranulocytosis | 3,593 | 3.93.8–4.0 | signal |
| Thrombocytopenia | 2,225 | 2.72.6–2.8 | signal |
| Serious infection | 7,734 | 2.72.6–2.7 | signal |
| Liver injury | 2,512 | 2.22.1–2.3 | signal |
| Anaemia | 2,457 | 2.22.1–2.3 | signal |
| Anaphylaxis / angioedema | 1,011 | 2.22.0–2.3 | signal |
| Kidney injury | 3,150 | 1.81.8–1.9 | raised |
| Gi bleeding | 1,118 | 1.61.5–1.7 | raised |
| Arrhythmia / qt | 1,182 | 1.61.5–1.7 | raised |
| Severe cutaneous reaction | 447 | 1.61.5–1.8 | raised |
| Interstitial lung disease | 562 | 1.61.4–1.7 | raised |
| Opportunistic infection | 791 | 1.61.4–1.7 | raised |
| Venous thromboembolism | 1,219 | 1.51.4–1.6 | raised |
| Fall / fracture | 2,117 | 1.51.4–1.6 | raised |
| Seizure | 1,063 | 1.41.4–1.5 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Nausea | 5,628 | 1.9 1.9–2.0ROR 2.0 · calibrated p 0.934 | 1.9 EB05 1.9 · IC025 +0.9 | Not in label — unassessed | age-adj. PRR 1.8 · serious PRR 2.2 | no trial arm names this drug |
| Myelosuppression | 5,180 | 47.9 46.5–49.3ROR 51.2 · calibrated p 1e-5 ✓ | 40.6 EB05 39.7 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 42.1 · serious PRR 29.3 · 92% clinician | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 4,957 | 2.4 2.3–2.4ROR 2.4 · calibrated p 0.838 | 2.3 EB05 2.3 · IC025 +1.2 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.1 · serious PRR 2.0 | no trial arm names this drug |
| Off label use (used outside approved label) | 4,929 | 1.5 1.5–1.6ROR 1.6 · calibrated p 0.677 | 1.5 EB05 1.5 · IC025 +0.6 | Reporting / coding artifact | age-adj. PRR 1.4 · serious PRR 1.7 | no trial arm names this drug |
| Headache | 4,496 | 1.9 1.9–2.0ROR 2.0 · calibrated p 0.933 | 1.9 EB05 1.9 · IC025 +0.9 | Not in label — unassessed | age-adj. PRR 1.5 · serious PRR 1.9 | no trial arm names this drug |
| Pyrexia (fever) | 4,389 | 3.4 3.3–3.5ROR 3.6 · calibrated p 0.470 | 3.4 EB05 3.3 · IC025 +1.7 3/3 methods agree | Not in label — unassessed | age-adj. PRR 3.0 · serious PRR 2.7 | no trial arm names this drug |
| Fatigue (tiredness) | 4,312 | 1.5 1.4–1.5ROR 1.5 · calibrated p 0.650 | 1.5 EB05 1.4 · IC025 +0.5 | Not in label — unassessed | age-adj. PRR 1.3 · serious PRR 1.5 | no trial arm names this drug |
| Vomiting | 3,991 | 2.3 2.2–2.4ROR 2.4 · calibrated p 0.878 | 2.3 EB05 2.2 · IC025 +1.1 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.1 · serious PRR 2.1 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 3,853 | 1.6 1.6–1.7ROR 1.6 · calibrated p 0.728 | 1.6 EB05 1.6 · IC025 +0.6 | Not in label — unassessed | age-adj. PRR 1.4 · serious PRR 1.6 | no trial arm names this drug |
| Pneumonia (lung infection) | 3,535 | 2.9 2.8–3.0ROR 3.0 · calibrated p 0.616 | 2.9 EB05 2.8 · IC025 +1.5 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.5 · serious PRR 2.2 | no trial arm names this drug |
| Pain | 3,151 | 1.4 1.3–1.4ROR 1.4 · calibrated p 0.565 | 1.4 EB05 1.3 · IC025 +0.4 | Not in label — unassessed | age-adj. PRR 1.4 · serious PRR 1.2 | no trial arm names this drug |
| White blood cell count decreased | 2,886 | 7.3 7.0–7.5ROR 7.5 · calibrated p 0.080 | 7.1 EB05 6.9 · IC025 +2.8 3/3 methods agree | Lab value / disease marker | age-adj. PRR 7.6 · serious PRR 7.1 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 2,789 | 0.6 0.5–0.6ROR 0.5 · calibrated p 0.065 | 0.6 EB05 0.5 · IC025 -0.9 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.6 · serious PRR 1.0 | no trial arm names this drug |
| Cough | 2,706 | 2.6 2.5–2.7ROR 2.7 · calibrated p 0.750 | 2.6 EB05 2.5 · IC025 +1.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.1 · serious PRR 2.5 | no trial arm names this drug |
| Dizziness | 2,635 | 1.4 1.4–1.5ROR 1.4 · calibrated p 0.595 | 1.4 EB05 1.4 · IC025 +0.4 | Not in label — unassessed | age-adj. PRR 1.3 · serious PRR 1.4 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Vaginal flatulence — n=119, PRR 170.7
- Deafness permanent — n=56, PRR 105.7
- Infusion site discharge — n=300, PRR 56.7
- Wound infection pseudomonas — n=53, PRR 54.6
- Myelosuppression — n=5,180, PRR 47.9
- Infective pulmonary exacerbation of cystic fibrosis — n=796, PRR 45.3
- Ejection fraction — n=78, PRR 41.0
- Cystic fibrosis respiratory infection suppression — n=119, PRR 40.6
- Osmotic demyelination syndrome — n=97, PRR 40.2
- Sensitisation — n=99, PRR 39.6
✓ A hand-written Bradford Hill causality assessment exists for this drug: Methotrexate Sodium ↔ Rheumatoid Arthritis.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Sodium Chloride?
In FDA FAERS, the most frequently co-reported reaction terms for Sodium Chloride are nausea, myelosuppression, dyspnoea, headache, pyrexia, fatigue. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Sodium Chloride have an FDA boxed warning?
No. The FDA label retrieved for Sodium Chloride has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Sodium Chloride causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 018a8807-1331-41c3-4889-c7ec502a9043, effective 20260309; matched on
openfda.generic_name.exact:"SODIUM CHLORIDE") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,234 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
SODIUM CHLORIDE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.